Publications by authors named "Jordan A Johnstone"
Cost-Effectiveness of Percutaneous Lymphatic Embolization for Management of Plastic Bronchitis.
World J Pediatr Congenit Heart Surg
July 2019
Article Synopsis
- - Plastic bronchitis is a serious complication for patients with single ventricle heart conditions after the Fontan procedure, often needing heart transplants when medical treatment fails, leading to a need for better treatment options like percutaneous lymphatic embolization.
- - A study assessed the cost-effectiveness of treatment strategies (medical management, lymphatic embolization, and heart transplantation) using a modified Markov model, analyzing costs and quality-adjusted life years (QALYs) over five years.
- - Results showed lymphatic embolization costs about $340,941, offering better survival rates compared to heart transplantation and medical management, making it a more cost-effective option at $192,105 and $68,030 incremental cost-effectiveness
Background The Fontan operation is performed for surgical palliation of single ventricle physiology. This operation is usually preceded by a superior cavopulmonary connection (SCPC); lymphatic abnormalities after SCPC may be demonstrated at MRI and prior to the Fontan operation. Purpose To determine if the degree of neck and thoracic lymphatic abnormalities at T2-weighted MRI in patients after superior cavopulmonary connection (SCPC) correlated with surgical outcomes from the Fontan procedure.
View Article and Find Full Text PDFRationale And Objectives: This study aimed to describe prenatal and postnatal imaging features and outcomes of neonates with neonatal lymphatic disorders (NLDs).
Materials And Methods: An institutional review board-approved search of the radiology database for patients with NLD identified five patients. Inclusion criteria include prenatal imaging (fetal magnetic resonance [MR] imaging and ultrasound) and postnatal three-dimensional T2 Sampling Perfection with Application optimized Contrasts using different flip angle Evolution (SPACE) and dynamic contrast-enhanced MR lymphangiography within 6 months of life.